FIELD: medicine; oncology.
SUBSTANCE: group of inventions is intended for immunotherapy of malignant tumors. Pharmaceutical composition is a vaccine inducing formation of anti-tumor antibodies. Vaccine contains immunogenic glycoconjugate Globo-H-KLH (OBI-822), in which molecules of tumor antigen Globo-H are covalently linked to molecules of structural subunits of hemocyanin KLH by one or more residues of amino acids. Said composition has an epitope ratio of Globo-H molecule / molecule of structural subunit KLH in range from 750 to 3000. In one embodiment, the Globo-H molecule is bound to KLH by covalent bonding with 4-(4-N-maleimidomethyl)cyclohexane-1-carboxylhydrazide (MMCCH). In another version, said composition may contain an adjuvant α-galactosylceramide(α-GalCer). In one embodiment, the method of treating a malignant tumor involves administering to a patient a therapeutically effective amount of said pharmaceutical composition. In another version, said composition is administered to an individual in order to obtain monoclonal antibodies for therapeutic or diagnostic use.
EFFECT: group of inventions enables to elicit a high level of the immune response directed to Globo-H.
46 cl, 7 tbl, 38 dwg, 9 ex
| Title | Year | Author | Number |
|---|---|---|---|
| NOVEL FUSION PROTEINS SPECIFIC FOR CD137 AND GPC3 | 2020 |
|
RU2814653C2 |
| FUSED POLYPEPTIDE WITH ANTI-CANCER ACTIVITY | 2016 |
|
RU2754466C2 |
| ARTIFICIAL ANTIGEN-PRESENTING CELLS AND METHODS FOR THEIR APPLICATION | 2018 |
|
RU2763798C1 |
| HER-2-DIRECTED ANTIGEN-BINDING MOLECULES CONTAINING 4-1BBL | 2019 |
|
RU2815451C2 |
| NOVEL FUSION PROTEIN SPECIFIC FOR CD137 AND PD-L1 | 2019 |
|
RU2818349C2 |
| FUSED MOLECULES DERIVED FROM CHOLIX-TOXIN FOR ORAL DELIVERY OF BIOLOGICALLY ACTIVE LOADS | 2015 |
|
RU2723178C2 |
| ANTIBODIES AGAINST XI CLOTTING FACTOR | 2017 |
|
RU2757314C2 |
| HIGH GLYCATED FUSED PROTEIN BASED ON HUMAN BLOOD COAGULATION FACTOR VIII, METHOD FOR PRODUCTION THEREOF AND USE THEREOF | 2016 |
|
RU2722374C1 |
| TUMOR-TARGETED AGONISTIC CD28-ANTIGEN-BINDING MOLECULES | 2019 |
|
RU2808030C2 |
| COMPOSITIONS FOR THE TREATMENT OF PATHOLOGICAL CONDITIONS OF CALCIFICATION AND THEIR APPLICATION METHODS | 2016 |
|
RU2757417C2 |
